Showing posts with label Pleural. Show all posts
Showing posts with label Pleural. Show all posts

Wednesday, May 4, 2011

Pleural Mesothelioma Cancer

Pleural mesothelioma is a disease that affects the lining of the lungs, or lung pleura. Sometimes doctors refer to this disease as mesothelioma of the pleura. It is a common misconception that mesothelioma is a type of primary lung cancer; it is not. Mesothelioma is a cancer of the serous membranes. These membranes enclose a number of organs throughout the midsection of the body, including the lungs. The most common type of mesothelioma, pleural mesothelioma, affects the serous membranes of the lungs.
Mesothelioma can also affect the serous membranes surrounding the abdomen, called peritoneal mesothelioma, and the membranes surrounding the heart, or pericardial mesothelioma. When mesothelioma spreads to the lungs from the serous linings of the lungs, abdomen or heart, it is considered secondary lung cancer. Also, pleural mesothelioma is sometimes referred to as an asbestos lung cancer. Technically, cancers that do not originate in the lungs are not considered lung cancer; thus, terms such as secondary lung cancer and asbestos lung cancer (pleural mesothelioma) are misleading. Asbestosis is a type of asbestos lung disease that does originate in the lungs and is often confused with mesothelioma.

Pleural Mesothelioma Cancer

Pleural mesothelioma cancer represents about 75 percent of all mesothelioma cases. This disease is caused by the inhalation of asbestos fibers, which then settle in the lungs. These asbestos fibers become imbedded in the lining of the lung (the pleura). Over time, they cause chronic inflammation that eventually leads to growth of cancerous tumors or, in some cases, asbestosis.
Pleural mesothelioma cancer normally appears as multiple tumor masses affecting the parietal surface (outside; further from the lung) and visceral surface (inside; closer to the lung) of the pleura. Typically, the parietal surface has greater involvement than the visceral. There is a slightly higher incidence of mesothelioma in the right lung, apparently due to the fact that the right lung is larger and has a greater amount of pleural surface area. Also, the lower lungs typically show more tumor masses than the upper lung. This is thought to be due to gravitational factors influencing how the asbestos fibers settle in the lungs after they have been inhaled.
Large growths in the pleura are normally noted in patients upon diagnosis. As the diseases progresses, these growths lead to a complete obliteration of the lung cavity. The tumors can spread from the lung pleura to other organs, including the heart and abdomen. Mesothelioma can also invade the lymph nodes and circulatory system.
Tumors unrelated to pleural mesothelioma also grow in the pleura. These tumors start in other parts of the body and metastasize to the pleura. The most common form of non-pleural mesothelioma cancer that occurs is lung cancer, representing about 36 percent of the cancer occurring in the pleura. The next most common forms are breast cancer (25 percent), ovarian cancer (5 percent) and gastric cancer (2 percent). Lymphoma also accounts for a small portion of cancers that metastasize to the pleura.

Pleural Mesothelioma Symptoms

The most common symptom for pleural mesothelioma patients is chest pain. But, the pain often is not associated directly with the lung pleura and often appears in the shoulder or upper abdomen. Shortness of breath, called dyspnea, is also a symptom. Cough, weight loss and anorexia are present in some patients, but are less common. Finally, the rapid growth of the pleural mesothelioma cancer tumors enlarges the pleural space, causing it to fill with fluid. Oftentimes, this buildup of fluid known as a pleural effusion causes the discomfort or pain associated with first detection of the disease.
Pleural mesothelioma patients display all three types of mesothelioma cancer cells: epithelioid mesothelioma, sarcomatoid mesothelioma and biphasic mesothelioma.

Pleural Mesothelioma Prognosis

Most patients' malignant mesothelioma prognosis is quite bleak. In a study involving 167 patients with proven pleural mesothelioma, the median survival rate of patients following diagnosis was 242 days. The survival rate was also affected by the type of mesothelioma cancer cells; patients with biphasic cell types have the shortest life expectancy.

Thursday, April 28, 2011

Phase III Clinical Trial on Pleural Mesothelioma

Do You Read All Of Blogs? Do you read all of the blogs published by medicineworld.org? Many of our bloggers are busy keeping you updated on the various health related topics. We publish the following blogs at this time.
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
Janet      
Phase III Clinical Trial on Pleural Mesothelioma Emory Winship Cancer Institute will be one of two facilities in Georgia to conduct a phase III clinical trial of Vorinostat (oral suberoylanilide hydromaxic acid) in patients with advanced cancerous pleural mesothelioma. The purpose of the study is to test the safety and efficacy of Vorinostat as well as to compare the overall survival associated with therapy of the drug.
A rare but devastating disease, it is estimated that 2,000 to 3,000 new mesothelioma cases will be diagnosed each year in the United States. Mesothelioma is cancer of the cells found in the mesothelium, which is the protective lining covering most of the internal organs of the body. Pleural mesothelioma is the most common type of mesothelioma, and it is identified by the presence of malignant cells located in the tissue outside of the lungs and inside of the ribs.
Vorinostat is an experimental drug that is believed to work against cancer cells. When cells become malignant, chemical reactions inside the cancer cell allow those cells to multiply out of control. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The principal investigator on the Vorinostat clinical trial at Winship is Dong M. Shin, MD, Professor of Hematology/Oncology and Otolaryngology; Director of Clinical and Translational Cancer Prevention Programs; and Co-Director of the Lung and Aerodigestive Tract Malignancies Program at Emory Winship Cancer Institute. Dr. Shin joined Winship in 2003 after more than 15 years as a faculty member at M.D. Anderson Cancer Center in Houston and the University of Pittsburgh Cancer Institute.
"This is a very important study for this terrible disease," said Dr. Shin. "As a second line treatment, there are currently no options other than this clinical trial."
Eligibility for the Vorinostat clinical trial requires a diagnosis of unidimensionally measurable cancerous pleural mesothelioma, which has progressed or relapsed following therapy with pemetrexed in combination with either Cisplastin or Carboplatin. For more information about this trial, contact Martha Forrester at 404-778-5849.
Source: Emory University
Did you know?
Emory Winship Cancer Institute will be one of two facilities in Georgia to conduct a phase III clinical trial of Vorinostat (oral suberoylanilide hydromaxic acid) in patients with advanced cancerous pleural mesothelioma. The purpose of the study is to test the safety and efficacy of Vorinostat as well as to compare the overall survival associated with therapy of the drug.
View the original article here
Related Posts Plugin for WordPress, Blogger...